Despite different initial triggers (LPS, β-amyloid, aging), primed microglia may converge on a common 'epigenetic priming signature' characterized by BRD4-occupied poised enhancers at NF-κB target genes (including TNF, IL1B, CCL2, and TREM2). This convergent chromatin remodeling would explain why BET inhibitors produce similar therapeutic effects regardless of priming stimulus, as they disrupt a shared downstream transcriptional amplifier rather than stimulus-specific upstream pathways. The testable prediction is that BRD4 ChIP-seq in microglia primed by distinct stimuli will reveal overlapping enhancer landscapes, and that CRISPR-mediated deletion of a representative converged enhancer will abrogate hyperinflammatory responses across all priming conditions.
Curated pathway from expert analysis
flowchart TD
A["BRD4 BET Bromodomain<br/>Transcription Amplification"]
B["NF-kB Enhancer<br/>Activity Amplification"]
C["Convergent NF-kB<br/>Enhancers Across Stimuli"]
D["Pro-Inflammatory Gene<br/>Expression Sustained"]
E["BET Inhibitor<br/>Therapeutic Vulnerability"]
F["BRD4 as<br/>Enhancer Amplification Target"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7No linked papers recorded for this hypothesis yet.
Median TPM across 13 brain regions for BRD4 from GTEx v10.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for BRD4.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF CRISPR-Cas9 editing deletes a representative convergent BRD4-occupied enhancer (chr11:60.5-60.7 Mb upstream of TREM2) in iPSC-derived microglia-like cells, THEN treatment with JQ1 (300 nM BET inhib | CRISPR-deleted cells show blunted inflammatory response (TNF release <50 pg/mL) across all challenge conditions compared to wild-type cells, with BET inhibitor | — no observation — | pending | 0.68 |
| IF primary murine microglia are primed with three mechanistically distinct stimuli (LPS 100 ng/mL, aggregated Aβ42 2 μM, and serum derived from 24-month-old mice), THEN BRD4 ChIP-seq will reveal stati | Peaks overlapping between all three conditions at minimum 5 of 8 tested NF-κB target loci, with Homer-defined enhancer signatures (H3K27ac+/BRD4+ co-occupancy) | — no observation — | pending | 0.75 |